PUBLISHER: The Business Research Company | PRODUCT CODE: 1889359
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889359
Diabetes stem cell therapy refers to a medical approach that uses stem cells to treat or manage diabetes by regenerating, replacing, or repairing damaged pancreatic cells, particularly insulin-producing beta cells. It is widely used in clinical research and regenerative medicine to improve blood glucose control, reduce diabetes-related complications, and support potential long-term disease management.
The primary types of therapies in the diabetes stem cell therapy market include preclinical and clinical phase 1 and 2 therapies. Preclinical therapies refer to treatments in the experimental stage, typically tested in laboratory and animal models to assess safety, efficacy, and potential therapeutic benefits before progressing to human clinical trials. These therapies include autologous, allogeneic, induced pluripotent, mesenchymal, and hematopoietic stem cell treatments, delivered through methods such as intravenous injection, intramuscular injection, intra-pancreatic injection, and local tissue delivery. They are applied in areas such as type 1 diabetes treatment, type 2 diabetes management, diabetic complication treatment, and islet cell transplantation, and are primarily utilized by hospitals, research institutes, diabetes clinics, and pharmaceutical companies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The diabetes stem cell therapy market research report is one of a series of new reports from The Business Research Company that provides diabetes stem cell therapy market statistics, including the diabetes stem cell therapy industry global market size, regional shares, competitors with the diabetes stem cell therapy market share, detailed diabetes stem cell therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetes stem cell therapy industry. This diabetes stem cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The diabetes stem cell therapy market size has grown rapidly in recent years. It will grow from $2.68 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be linked to the growing prevalence of diabetes, rising healthcare expenditure, increasing awareness about regenerative therapies, growing government support for stem cell research, and increasing availability of clinical trial infrastructure.
The diabetes stem cell therapy market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be driven by increasing demand for personalized medicine, a rising number of stem cell therapy clinics, growing investment in biotechnology, increasing favorable reimbursement policies, and growing adoption of advanced therapeutic solutions. Major trends in the forecast period include technological advancements in stem cell engineering, innovations in cell delivery systems, developments in regenerative medicine protocols, integration of artificial intelligence in therapy design, and collaborations between biotech companies and research institutes.
The growing need for novel treatments is expected to drive the growth of the diabetes stem cell therapy market in the coming years. Novel treatments are therapies that use new mechanisms, targets, or approaches not previously available for disease management. This demand is rising due to the increasing prevalence of complex and chronic diseases, as conventional therapies often fail to provide effective or long-term solutions. Diabetes stem cell therapy addresses this need by offering regenerative solutions that can restore pancreatic function, reduce insulin dependence, and potentially provide a long-term cure for diabetes. For instance, in January 2025, the National Center for Biotechnology Information (NCBI) reported that 1,035 new drugs were approved, of which 337 were novel drugs, including 81 first-in-class therapies, accounting for 24% of all novel approvals. Consequently, the growing need for novel treatments is fueling the diabetes stem cell therapy market.
Companies in the diabetes stem cell therapy market are focusing on advances in biotechnology, stem cell research, and regenerative medicine to provide cellular therapies that restore insulin production and improve glycemic control in patients with type 1 diabetes. These approaches involve the use of living cells, tissues, and molecular techniques to repair, replace, or regenerate damaged organs or cells, offering advanced treatment options for chronic diseases. In June 2023, CellTrans Inc., a US-based biotechnology firm, received FDA approval for Lantidra, the first allogeneic pancreatic islet cellular therapy made from deceased donor pancreatic cells for adults with type 1 diabetes experiencing recurrent severe hypoglycemia. Administered via a single infusion into the hepatic portal vein, the transplanted islet beta cells secrete insulin, allowing some patients to achieve insulin independence for one year or more, with cases extending up to five years, significantly improving disease management, glycemic control, and quality of life.
In June 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Sigilon Therapeutics Inc. for $309.6 million. Through this acquisition, Eli Lilly aims to strengthen its capabilities in encapsulated cell-therapy solutions for type 1 diabetes by integrating Sigilon's shielded-cell technology into its portfolio. Sigilon Therapeutics Inc. is a US-based biopharmaceutical company developing stem cell-based therapies for type 1 diabetes.
Major companies operating in the diabetes stem cell therapy market are Bristol-Myers Squibb Company, Gilead Sciences Inc., Mesoblast Limited, Evotec SE, Swiss Medica Stem Cells SA, Aspect Biosystems Ltd., Celltex Therapeutics Corporation, Adocia SA, Seraxis Inc., BrainStorm Cell Therapeutics Inc., Sernova Corporation, Betalin Therapeutics Ltd., NextCell Pharma AB, PharmaCyte Biotech Inc., Global Institute for Stem Cell Therapy and Research, Throne Biotechnologies Inc., Orgenesis Inc., Holostem Terapie Avanzate S.r.l., Anterogen Co. Ltd., Juventa Regenerative Medicine Inc.
North America was the largest region in the diabetes stem cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetes stem cell therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the diabetes stem cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetes stem cell therapy market consists of revenues earned by entities by providing services such as stem cell transplantation services, quality control testing, logistics and cryopreservation services, and patient monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes stem cell therapy market also includes sales of bioreactors, syringes, cell therapy kits, diagnostic kits, and laboratory consumables. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetes Stem Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetes stem cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for diabetes stem cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes stem cell therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.